ArticleFrontiers in endocrinology2025
Identification of novel variants underlying non-syndromic primary ovarian insufficiency using a targeted NGS gene panel.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Primary ovarian insufficiency (POI) affects 1-4% of women and is associated with infertility and reduced life expectancy. Most cases are idiopathic, and a genetic alteration is often the most plausible cause. In this study, we investigated whether targeted next-generation sequencing (NGS) analysis in combination with the OvAge Methods: We enrolled 100 women with nsPOI and 200 healthy controls. A targeted NGS panel covering 72 genes potentially involved in POI was developed using Ampliseq technology (ThermoFisher Scientific). Various bioinformatic tools (Polyphen, Sift, CADD, MutationTaster and the Grantham score) were used to identify potentially pathogenic variants according to ACMG guidelines, while tools such as STRVCTVRE, CADD-SV and X-CNV were used to predict pathogenicity of CNV calls. Results: Using this panel, we identified mutations in 60% (N=60) of the patients, of whom 23% carried likely pathogenic or pathogenic mutations, and 37% had variants of uncertain significance (VUS). Among these 60 patients, 37 had monogenetic variants and 23 had mutations in two or more genes. In total, we identified 42 genes affected in our Italian of nsPOI cohort. The most frequently mutated genes in our cohort included DNAH5, LAMC1, ADAMTS1/19, HSD17B4, HK3 and AR. Additionally, we detected CNVs in the SYCE, DUSP22 and INHBB genes. Most of the altered genes in our cohort are involved in DNA repair, meiosis and signal transduction. Gene Ontology (GO) analysis revealed that the mutated genes play a key role in oocyte differentiation, folliculogenesis and follicular maturation. Discussion: Our main conclusion is that the development of a test integrating clinical, ultrasound, biochemical (OvAge©) and genetic data could substantially enhance early identification of women at risk of POI and offer opportunities for fertility preservation, such as oocyte cryopreservation or prioritizing reproductive efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.